Laurus Labs has signed an agreement to buy a 60% stake in Galenvs Sciences, a Canada-based biotech company, according to multiple reports. The deal is framed as a strategic investment, with the acquisition tied to a stated pre-money valuation.
Business Line also links the transaction to Laurus Labs’ recent quarterly performance, reporting that its Q2 net profit more than doubles to ₹441 crore. Across the coverage, the emphasis differs: one outlet focuses directly on the acquisition agreement and stake percentage, while the other pairs the deal with the company’s financial update. Despite these different lead angles, both accounts describe the same core transaction—Laurus Labs acquiring majority control through a 60% purchase.
The reports collectively indicate that the acquisition agreement includes a valuation reference of $3.5 million (pre-money). They do not provide additional details on timing, regulatory approvals, or use of proceeds in the information provided.